Holen Sie sich die Stockscreener-App
296.88
0.60%
1.78
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$295.10
Offen:
$297.06
24-Stunden-Volumen:
2.41M
Relative Volume:
0.93
Marktkapitalisierung:
$159.63B
Einnahmen:
$34.13B
Nettoeinkommen (Verlust:
$5.93B
KGV:
27.09
EPS:
10.96
Netto-Cashflow:
$10.92B
1W Leistung:
-3.16%
1M Leistung:
+2.19%
6M Leistung:
+4.02%
1J Leistung:
-11.52%
1-Tages-Spanne:
$292.59
$298.52
1-Wochen-Bereich:
$292.59
$306.00
52-Wochen-Spanne:
$253.30
$339.17
Amgen Inc Stock (AMGN) Company Profile
Firmenname
Amgen Inc
Sektor
Telefon
(805)447-1000
Adresse
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Vergleichen Sie AMGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
296.88 | 158.68B | 34.13B | 5.93B | 10.92B | 10.96 |
|
LLY
Lilly Eli Co
|
762.33 | 664.39B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
167.33 | 396.75B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
195.22 | 333.89B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.30 | 220.18B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
79.29 | 196.16B | 63.62B | 16.41B | 17.04B | 6.49 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-20 | Fortgesetzt | Guggenheim | Neutral |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-14 | Herabstufung | Truist | Buy → Hold |
| 2024-09-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Hochstufung | Truist | Hold → Buy |
| 2023-10-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-17 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-24 | Bestätigt | Oppenheimer | Outperform |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Bestätigt | Truist | Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Underperform |
| 2022-10-31 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-09 | Bestätigt | Barclays | Equal Weight |
| 2022-02-09 | Bestätigt | Jefferies | Buy |
| 2022-02-09 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-09 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-09-23 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Eingeleitet | Daiwa Securities | Buy |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Hochstufung | Truist | Hold → Buy |
| 2020-10-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Herabstufung | Truist | Buy → Hold |
| 2020-10-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Fortgesetzt | Guggenheim | Neutral |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-03-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-17 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-05-23 | Hochstufung | Citigroup | Neutral → Buy |
Alle ansehen
Amgen Inc Aktie (AMGN) Neueste Nachrichten
Federated Hermes Inc. Has $634.68 Million Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
UBS Raises PT on Amgen Inc. (AMGN) to $326 From $315, Keeps a Neutral Rating - MSN
AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND - PR Newswire
Amgen’s Promising Phase 3 Study on Dazodalibep for Sjögren’s Syndrome: A Potential Game-Changer - TipRanks
Amgen’s Latest Clinical Study: A Potential Game-Changer in Lung Cancer Treatment? - TipRanks
Amgen’s Tarlatamab Study: A Potential Breakthrough in SCLC Treatment - TipRanks
Amgen’s Promising Heart Failure Study: A Potential Game-Changer? - TipRanks
Amgen’s Promising Phase 3 Study for Metastatic Colorectal Cancer - TipRanks
Amgen’s New Study on AMG 410: A Potential Game-Changer in Cancer Treatment - TipRanks
Amgen’s New Melanoma Study: A Potential Game Changer? - TipRanks
Amgen’s Tarlatamab Study: A Potential Game-Changer in Lung Cancer Treatment - TipRanks
Amgen’s Promising Phase 3 Study on Weight Loss Drug Maridebart Cafraglutide - TipRanks
Amgen’s Promising Study on Rocatinlimab for Atopic Dermatitis: A Potential Game-Changer - TipRanks
Amgen’s CodeBreaK 202: A New Front-Line Therapy Study for Advanced Lung Cancer - TipRanks
Amgen’s Phase 2 Study on HZN-1116: A Potential Breakthrough for Sjögren’s Syndrome - TipRanks
Amgen’s Golden Gate Study: A Promising Leap in Leukemia Treatment - TipRanks
Amgen’s Phase 3 Obesity Drug Trial: A Potential Game Changer? - TipRanks
Amgen’s New Study on ABP 234: A Potential Game-Changer in Lung Cancer Treatment - TipRanks
Is Amgen (NASDAQ:AMGN) A Risky Investment? - simplywall.st
Torray Investment Partners LLC Trims Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Natixis Advisors LLC Has $101.15 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Arkadios Wealth Advisors Boosts Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Dearborn Partners LLC Has $654,000 Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Geneos Wealth Management Inc. Purchases 5,500 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Mitchell Sinkler & Starr PA Reduces Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Foundations Investment Advisors LLC Increases Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Mackenzie Financial Corp Has $55.12 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
What markets is CRUS expanding into Is Amgen Inc. stock a good long term investment optionBeginner Investor Report With Low Risk - jammulinksnews.com
Amgen Sets Q2 2025 Earnings Call: CEO Bradway to Present Financial Results August 5 - Stock Titan
Amgen’s Promising Oncology Study: A Closer Look at AMG 193 and IDE397 - TipRanks
Why is Amgen Inc. stock attracting strong analyst attentionRetirement Planning Review With Proven Results - jammulinksnews.com
Gear Up for Amgen (AMGN) Q2 Earnings: Wall Street Estimates for Key Metrics - Yahoo.co
Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial - Yahoo Finance
Howard Capital Management Inc. Sells 2,099 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Tredje AP fonden Boosts Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Vestcor Inc Sells 6,075 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
TD Asset Management Inc Sells 27,366 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Purkiss Capital Advisors LLC Buys Shares of 863 Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Kinsale Capital Group Inc. Buys 4,030 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by TCW Group Inc. - MarketBeat
ARK Investment Management LLC Trims Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Assetmark Inc. Sells 118,002 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Is Amgen Inc. a Top Dividend Stock to Watch in 2025Investment Strategy Designed for Capital Protection - metal.it
Biotechnology Market is evolving rapidly Through 2025 To 2032 | Abbott Laboratories, Amgen Inc., GlaxoSmithKline - openPR.com
Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue? - Yahoo Finance
Harvest Fund Management Co. Ltd Purchases 22,759 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Rises 0.75 Despite 27.65% Volume Drop to 430M 272nd in Market as Golden Cross and Earnings Outlook Fuel Optimism - AInvest
Viridian inks Japan licensing deal as it seeks to take on Amgen's Tepezza next year - Endpoints News
Woodard & Co. Asset Management Group Inc. ADV Decreases Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Mediolanum International Funds Ltd - MarketBeat
Valley Wealth Managers Inc. Has $27.15 Million Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Finanzdaten der Amgen Inc-Aktie (AMGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):